Risedronate reduces postoperative bone resorption after cementless total hip arthroplasty

Summary Forty-three patients who had undergone cementless THA were randomly assigned to receive no osteoactive drug or oral risedronate for 6 months. Postoperative decrease of BMD in the risedronate group was significantly lower than that seen in the control group in zones 1, 2, 3, 6, and 7. Introduction Proximal bone resorption around the femoral stem often has been observed after total hip arthroplasty (THA), could lead to late stem loosening. We previously reported the efficacy of etidronate on periprosthetic bone resorption after cementless THA. Recently risedronate is suggested to be effective for the prevention and treatment of for osteoporosis. The purpose of the present study was to evaluate the effects of risedronate on periprosthetic bone loss after cementless THA. Methods Forty-three patients who had undergone cementless THA were randomly assigned to receive no osteoactive drug (21 patients) or oral risedronate 2.5 mg/day (22 patients) for 6 months. Three patients were eliminated from the risedronate group because of dyspepsia. Periprosthetic bone mineral density (BMD) in seven regions of interest based on the zones of Gruen et al. was measured with dual energy X-ray absorptiometry at 3 weeks and 6 months postoperatively. Results At 6 months after surgery, postoperative decrease of BMD in the risedronate group was significantly lower than that seen in the control group in zones 1, 2, 3, 6, and 7 (p < 0.05, p < 0.01, p < 0.01, p < 0.05, and p < 0.05, respectively). Conclusion These outcomes suggested that risedronate might reduce the periprosthetic bone resorption after cementless THA.     

Clinical significance of risedronate for patients with prostate cancer receiving androgen deprivation therapy

PURPOSE: Androgen deprivation therapy (ADT) in patients with prostate cancer is associated with bone loss. We investigated the effectiveness of risedronate about a decreasing bone mineral density in patients with prostate cancer on ADT. MATERIAL AND METHOD: A prospective study was conducted in Kitasato University Hospital from April 2004 to October 2006. A total of 69 men with prostate cancer were assigned to receive either oral risedronate or none during ADT (hormone na?ve). The treatment group was 58 men and taking 2.5 mg risedronate per day. The control group was 11 men. At baseline, we assessed BMD (bone mineral density) by DEXA and urinary NTX, and measured for these changes every 6 months. RESULT: At baseline, each BMDs had no significant difference at the lumber and total hip. At the first 6-month stage, the change in BMD percentage between the 2 groups was statistically significantly different at lumber (p = 0.002) and total hip (p = 0.038). At the 12-month stage, the change in the BMD percentage between the 2 groups was statistically significantly different at the lumber (p = 0.038). And each difference made out that the risedronate group was preserving BMD. In urinary NTX, bone turn over was statistically significantly decreased with the risedronate group compared with the control group at the 12-month stage (p = 0.017). CONCLUSION: We assure the beginning of bone loss at an early date (6 months) with ADT. Daily oral risedronate in patients with receiving ADT reduces bone mineral loss and maintain BMD.     

珊瑚型人工髋关节置换术的临床随访及松动原因的分析

自１９８３年至今应用珊瑚型人工髋关节置换术共５４例６０髋。其中人工全髋关节置换术３４例４０髋，人工股骨头置换术２０例２０髋。在５４例６０髋珊瑚型人工髋关节置换术中，有３７髋随访６个月～１３年，平均随访时间约７年，疗效满意率为８５．１％，其中假体松动４例占１４．８％，髋臼松动２例７．４％。假体松动原因是假体与股骨负重界面之间没有达到稳定接触，假体与髓腔形状不相匹配，修整髓腔松质骨时，髓腔扩大器应比假体小一号，避免假体与界面存留缝隙。对于髋臼发育不良的患者应避免髋关节旋转中心向外侧移位，应向内上方加深髋臼以减少水平移位距离，其次髋臼植骨加盖勿在负重区。     

定制人工股骨头治疗股骨上段转移性肿瘤

目的探讨股骨上段转移性肿瘤定制人工股骨头置换治疗的近期疗效。方法对14例股骨上段转移性肿瘤患者行瘤段骨切除和定制人工股骨头置换手术治疗。肾功能正常患者术后2周开始二膦酸盐类药物口服,并对患者的临床表现、局部影像学、疼痛情况及患侧肢体术后功能进行观察评定。结果术后患髋疼痛基本缓解,关节活动功能恢复满意,可满足日常行走和负重需要。14例均获随访,时间6～38个月。随访期内无假体松动、脱位及假体周围骨折等发生,手术局部肿瘤无复发。术后3个月时髋关节Harris评分:优4例,良9例,可1例。结论对股骨近段转移性肿瘤采用定制人工股骨头重建,可有效缓解疼痛,保留肢体功能,提高生存质量。     

Changes of femoral periprosthetic bone mineral density 6 years after treatment with alendronate following total hip arthroplasty

Earlier osteodensitometric results of femoral periprosthetic bone showed that postoperative antiresorptive treatment with alendronate following total hip arthroplasty (THA) reduces the periprosthetic bone loss that commonly occurs in the first months after surgery. However, whether alendronate can prevent periprosthetic bone loss over the long term, or if bone loss occurs after discontinuing alendronate is unknown. Femoral periprosthetic bone mineral density (BMD) was assessed in 49 patients 6 years after cementless total hip arthroplasty using dual energy X‐ray absorptiometry. Twenty‐nine patients were treated postoperatively with alendronate and 20 control patients received no treatment. All patients were followed up at 12 months after surgery in a prospective randomized study. The bone mineral density was evaluated in 7 regions of interest according to the Gruen protocol. Six years after total hip arthroplasty, no significant changes were detected in femoral periprosthetic BMD when compared with results at 1 year, and the bone loss in patients with postoperative alendronate treatment was still significantly less than those without treatment. These results suggest that the prevention of femoral periprosthetic bone loss following THA achieved by postoperative antiresorptive treatment with alendronate is of long‐standing effect, and further bone loss does not occur after the first postoperative year. © 2008 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 27:183–188, 2009     

髋臼内陷症的全髋关节置换术

目的 探讨全髋关节置换术治疗髋臼内陷症的手术操作方法和临床疗效.方法 2003年6月至2008年5月,采用全髋关节置换术治疗髋臼内陷症31例35髋,男16例18髋,女15例17髋;年龄36～71岁,平均52.2岁.手术均采用后外侧入路,股骨头取出困难时采用逆行取出法,分别处理髋臼环和髋臼底,取自体松质颗粒骨修复骨缺损,采用压配方式植入非骨水泥型全髋关节假体.术后1、3、6、12个月门诊随访,以后每年随访1次,随访时采用Harris髋关节评分评估髋关节功能,摄X线片观察假体是否有松动和再次内陷,植骨是否愈合.结果 全部病例随访19～152个月,平均46.5个月.1例患者术后第2天出现右下肢深静脉血栓,经抗凝处理后痊愈;1例术后2个月出现轻度大腿痛,无特殊处理,术后6个月消失,无其他并发症发生.术前Harris髋关节评分平均(48.9±6.5)分,末次随访增至平均(91.2±5.7)分,较术前平均改善42.3分.X线片显示所有假体均获得骨性稳定,无松动和再次内陷,术后平均6个月植骨愈合.结论 对于内陷髋臼,采用不同于普通全髋关节置换的手术技术,外移髋臼至旋转中心,用植骨修复骨缺损,选择非骨水泥型假体重建髋臼,可获得较好的临床效果,髋臼松动和再次内陷发生率低.

Abstract：

Objective To evaluate the clinical outcome of total hip arthroplasty (THA) for protrusio acetabuli. Methods Between 2003 to 2008, 31 patients(35 hips) with protrusio acetabuli were treated with THA, including 16 males (18 hips) and 15 females (17 hips). The age ranged from 36 to 71 years (average age 52.2 years). The femoral heads were moved out with retrograde method when necessary via posterior-lateral hip incision. The acetabular loops and bottoms were prepared respectively. Auto-bone grafting was used to repair acetabular defects and cementless prostheses were planted with press-fit skills. At follow-up visit,the hip functions were evaluated by Harris score. The loosening, re-protrusion and the union of graft bone was judged by X-ray. Results The mean follow-up was 46.5 months (19-152 months). One patient developed DVT on the second day post-operatively who recovered well after anticoagulation treatment. One patient complained of gentle thigh pain which disappeared at 6 months. No other complication was found. The mean Harris scores had improved from 48.9±6.5 pre-operatively to 91.2±5.7 post-operatively. All prostheses acquired bone stabilization with no sign of loosening and re-protrusion and the grafts bone were healed at a mean 6 months according to X-ray. Conclusion THA with acetabular bone grafting and cementless component for protrusio acetabuli have acquired excellent results and prevented loosening and re-protrusio effectively.     

No effect of risedronate on femoral periprosthetic bone loss following total hip arthroplasty: A 4-year follow-up of 61 patients in a double-blind,randomized placebo-controlled trial

Background and purpose

We have previously shown that during the first 2 years after total hip arthroplasty (THA), periprosthetic bone resorption can be prevented by 6 months of risedronate therapy. This follow-up study investigated this effect at 4 years.

Patients and methods

A single-center, double-blind, randomized placebo-controlled trial was carried out from 2006 to 2010 in 73 patients with osteoarthritis of the hip who were scheduled to undergo THA. The patients were randomly assigned to receive either 35 mg risedronate or placebo orally, once a week, for 6 months postoperatively. The primary outcome was the percentage change in bone mineral density (BMD) in Gruen zones 1 and 7 in the proximal part of the femur at follow-up. Secondary outcomes included migration of the femoral stem and clinical outcome scores.

Results

61 of the 73 patients participated in this 4-year (3.9- to 4.1-year) follow-up study. BMD was similar in the risedronate group (n = 30) and the placebo group (n = 31). The mean difference was −1.8% in zone 1 and 0.5% in zone 7. Migration of the femoral stem, the clinical outcome, and the frequency of adverse events were similar in the 2 groups.

Interpretation

Although risedronate prevents periprosthetic bone loss postoperatively, a decrease in periprosthetic BMD accelerates when therapy is discontinued, and no effect is seen at 4 years. We do not recommend the use of risedronate following THA for osteoarthritis of the hip.Adaptive bone remodeling around the femoral stem following total hip arthroplasty (THA) results in regional loss of bone mass, especially in proximal parts of the femur—most of which takes place within the first postoperative year (Bodén et al. 2006, Sköldenberg et al. 2006). Periprosthetic bone loss may predispose to periprosthetic fracture, aseptic loosening, and difficulties at revision surgery (Lindahl 2007, Streit et al. 2011, Sköldenberg et al. 2014).The bisphosphonate (BP) risedronate has been used successfully to prevent osteoporotic fractures, mainly in the hip and vertebrae, by inhibiting osteoclast activity (McClung et al. 2001). In recent years, the possible use of BPs to prevent or ameliorate periprosthetic adaptive bone resorption, osteolysis, and implant migration has been investigated thoroughly in animal models and humans. The short-term results of several studies showing the effects of postoperative BP treatment in reducing periprosthetic bone loss up to a year after the arthroplasty have already been published (Venesmaa et al. 2001, Wilkinson et al. 2001, Hennigs et al. 2002, Wilkinson et al. 2005, Arabmotlagh et al. 2006).We have previously found that risedronate given once a week for 6 months after THA reduces periprosthetic bone resorption around an uncemented femoral stem in the first and second postoperative year (Sköldenberg et al. 2011). We now report the 4-year outcome in the same cohort.     

Urinary concentration of collagen metabolites in endoprosthesis loosening

Aseptic loosening is the most common long-term complication in arthroplasty. Loosening is in every case associated with bone resorption at the interface that leads to bone defects and complicates the revision. The diagnosis of aseptic loosening is based on clinical and radiological evaluation. Especially in clinically asymptomatic cases an early diagnosis with these methods is difficult. In our study we wanted to evaluate the diagnostic value of biochemical markers of the bone resorption in aseptic loosening. We compared 58 patients with proven implant loosening during surgery with 67 patients without clinical or radiological signs of loosening. We measured the crosslinks pyridinoline and hydroxypyridinoline in urine samples. In contrast to Schneider et al. [increased urinary crosslink levels in aseptic loosening of total hip arthroplasty, J. Arthroplasty 1995; 13 (6): 687-692] we found no significant differences between loose and asymptomatic hip or knee prosthesis. Also no correlation between the size of the acetabular defects of loose hip implants and the urinary crosslink excretion was measurable. Our results show no or only little diagnostic value of the urinary crosslinks pyridinoline and deoxypyridinoline in aseptic loosening of total hip and knee arthroplasty.     

Monitoring of IL-6 levels in patients after total hip joint replacement]

Total hip replacement became a method of choice in treatment of the severe osteoarthritis. Despite the progress in constructing the implants and also the surgical technique, the number of complications rises together with the number of arthroplasties performed. The periprosthetic osteolysis and its consequence--the loosening is the one of the greatest problems of today's joint replacement. It creates the main obstacle for the long-term efficiency of the total hip arthroplasty. It was proved by the numerous research, wear debris of the implant induce the chronic periprosthetic inflammatory process. Many studies emphasize the influence of the proinflammatory cytokines on the bone metabolism. The aim of the study was the evaluation of the inflammatory process in patients with the severe osteoarthritis before the surgery and in subsequent periods after total hip replacements and also in patients with the aseptic loosening of the endoprosthesis, by the monitoring the levels of IL-6 in serum of the peripheral blood. The results suggest, that in patients following THA with the elevated level of IL-6, the inflammatory process was present. This inflammation may lead in future to the aseptic loosening of the implant.     

Bone regeneration 6 years after impaction bone grafting: a PET analysis

BACKGROUND: Impacted morselized bone allograft in revision total hip arthroplasty for prosthetic loosening has gained widespread clinical use during the last decades. The clinical results are good but little is known about the bone regeneration in the graft. PATIENTS AND METHODS: 5 patients were revised with impaction of morselized frozen allograft and a cemented total hip arthroplasty (THA) due to loosening and osteolysis of a primary THA. We used positron emission tomography ([18F]-fluoride PET) to produce quantitative images of new bone formation in the allograft surrounding the femur stem 6 years after surgery. RESULTS: The 5 patients had previously been analyzed by [18F]-fluoride PET during the first year after surgery (S?rensen et al. 2003). During the first year, bone formation proceeded through the graft layer and reached the cement layer surrounding the femoral stems. The clinical and radiographic results were excellent at 6 years. PET analyses at 6 years showed that the bone metabolism was significantly reduced in most areas of the proximal femur, compared to the elevated activity during the first year after surgery, and also normalized compared to the contralateral healthy femur. Graft bone metabolism distal to the stem tip remained slightly increased. Small patchy areas of increased uptake remained along the proximal femoral stem, probably reflecting small volumes of fibrous healing. INTERPRETATION: The metabolism of the allografted bone had normalized compared to native bone, indicating full regeneration throughout the graft--and a good long-term prognosis for implant fixation.     

Cyclic therapy with etidronate has a therapeutic effect against local osteoporosis after cementless total hip arthroplasty

Proximal bone resorption around the femoral stem is one of the major complications of cementless total hip arthroplasty (THA). The potential complications resulting from proximal bone resorption include femoral fracture and late stem loosening. The purpose of this study was to evaluate the effects of cyclic therapy with etidronate on periprosthetic bone mineral density (BMD) after cementless THA. Fifty-two patients who had undergone cementless THA were randomized for this study. Group A consisted of 30 hips in 29 patients without osteoactive drugs. Group B consisted of 23 hips in 23 patients with cyclic therapy with etidronate (i.e., 400 mg/day of oral etidronate for 2 weeks followed by 12 weeks of 500 mg/day of calcium lactate and repeated every 14 weeks), one of whom was excluded from the study because of side effects attributed to the drug. Periprosthetic BMD in seven regions of interest based on the zones of Gruen et al. (Clin. Orthop. 141 (1979), 17-27) was measured with dual energy X-ray absorptiometry (DXA) at 3 weeks, 6 months, and 12 months postoperatively. The postoperative decreases of BMD in group B were significantly lower than those in group A in zones 1 and 7 (P < 0.05 and P < 0.05, respectively) at 6 months and in zones 1, 2, 6, and 7 (P < 0.05, P < 0.05, P < 0.05, and P < 0.001, respectively) at 12 months. The BMD change appeared to be stabilized at 6 months in all zones in group B, while in group A there was a progressive decrease of average BMD (6.1%) in zone 7 between 6 months and 12 months. These findings suggested that cyclic therapy with etidronate may help to reduce the resorptive changes in the proximal part of the femur after cementless THA. Further follow-up study with larger populations will be required to define the potential efficacy of intermittent cyclic etidronate therapy on postoperative bone loss.     

Proximal femoral allografts in revision total hip arthroplasty

Patients with total hip arthroplasty (THA) and aseptic loosening associated with severe bone deficiency were treated with freeze-dried bone allografts of the proximal one-third of the femur. Twenty-two of the first 25 patients were available for review with an average follow-up period of 28 months. Significant functional improvement was obtained in 16 patients (73%). The following complications occurred with allograft revisions: dislocation, wound hematoma, joint instability, nonunion, implant failure, and acetabular loosening. Nine patients required additional surgical procedures. There have been no infections or rapid lysis indicative of an allograft rejection phenomenon. The 73% success at the two-year postoperative interval of incorporation of freeze-dried allografts for salvage situations has been encouraging. However, the long-term durability of these grafts is not known and will require further follow-up study.     

Changes in bone resorption markers among Japanese patients with postmenopausal osteoporosis treated with alendronate and risedronate

We compared the abilities of alendronate and risedronate to reduce levels of urinary cross-1inked N-telopeptides of type I collagen (NTX) in Japanese postmenopausal women. The patients were randomly divided into two groups (alendronate, 5 mg/day, n = 61; risedronate, 2.5 mg/day, n = 60). All patients had taken all medication prescribed for the first month and at least 90% of that prescribed for each of the following 6 months. Urinary NTX was measured at baseline, as well as at 1 and 6 months after starting treatment. According to the guidelines of the Japan Osteoporosis Society, the minimum significant change (MSC) for urinary NTX is defined as a 35% decrease from baseline and the cutoff level for a high risk of future fracture is 54.3 nmol bone collagen equivalent (BCE)/mmol·Cr. The NTX reduction rates at 1 and 6 months were greater with alendronate than with risedronate, but the difference was not significant. The rate of patients with a reduction in the MSC at 1 month was greater with alendronate than with risedronate, but the difference did not reach significance. Alendronate reduced NTX at 1 month significantly more in patients with a high risk of fracture than risedronate, but the difference was no longer significant at 6 months. The rate of MSC did not significantly differ between the two groups. In conclusion, alendronate decreases bone resorption markers more obviously and rapidly than risedronate, especially in high risk for fracture, but not significantly according to the guidelines of the Japan Osteoporosis Society.     

全髋关节置换术治疗成人髋关节发育不良

目的探讨全髋关节置换术(THA)治疗成人髋关节发育不良的临床疗效。方法采用THA治疗45例髋关节发育不良患者(50髋)。记录术后感染、髋关节脱位、假体松动、神经损伤情况,末次随访时采用Harris评分评定髋关节功能。结果患者均获得随访,时间2~65(24.1±16.0)个月。术后无感染、髋关节脱位、神经损伤等并发症发生。Harris评分由术前7~77(38.0±15.4)分增加到末次随访68~96(87.2±6.0)分,末次随访与术前比较差异有统计学意义(P<0.05)。末次随访时,所有患者患侧髋关节疼痛症状消失,关节活动功能满意;摄髋关节X线片复查显示关节假体位置、宿主骨对臼杯覆盖良好,假体骨骼界面稳固、无松动。结论THA治疗成人髋关节发育不良疗效满意,术中髋臼处理、真臼重建以及股骨假体的选择与安放是手术成功的关键因素。     

人工髋关节翻修术86例临床分析

目的：评价人工髋关节翻修术的临床疗效并探讨相关影响因素。方法：人工髋关节置换病例86例髋（对所有患者进行问卷调查、髋关节功能检查,并进行术前、术后Harris评分,术后疼痛发生评估及X线分析。结果：所有病例均获随访8个月～6年,平均38．9个月,无感染、假体松动等症发生;髋关节活动范围明显改善,Harris评分术前平均42分（30～53分）,随访时平均89分（73～97分）,其中优51,良29例,可6例,优良率93．02％;X线评价：无假体移位下沉等不稳现象,假体周围均无新出现的透亮带。结论：人工节翻修术近期疗效显著;髋关节翻修术中髋臼重建需充分术前准备,术中选择合适的假体及植骨方式。     

Decreased Periprosthetic Bone Loss in Patients Treated with Clodronate: A 1-Year Randomized Controlled Study

The efficacy of clodronate to reduce bone loss around uncemented stems after total hip arthroplasty (THA) was evaluated. Ninety-one patients operated with uncemented THA were randomized to receive either intramuscular clodronate at a dose of 100 mg weekly for 12 months or no treatment. Periprosthetic and contralateral bone mineral density (BMD) scans were performed and biochemical markers of bone turnover measured at baseline and at 3, 6, and 12 months. At month 12, with the exception of Gruen zones 4 and 5, patients treated with clodronate showed less bone loss at all zones, reaching statistical significance (P < 0.05) in Gruen zones 2 and 6 (difference of 6.6 and 5.9%, respectively). Analysis of data according to gender revealed sex-related differences in bone loss and efficacy of treatment. After 12 months, the difference in bone loss between treated and untreated women in five out of seven Gruen zones ranged from 6.2 to 13.3% (SS at zones 2 and 6), whereas comparison between treated and untreated men showed no BMD differences in all zones (P > 0.05). Median percent changes in serum levels of markers of bone metabolism by gender were consistent with BMD changes. A 1-year treatment with intramuscular clodronate determined a significant reduction of bone loss after THA. This was mainly attributed to its greater efficacy in the female population, which is at higher risk for bone loss. This observation suggests the need for the characterization of high-risk subjects as potential candidates for prevention strategies.     

Cemented revision total hip arthroplasty with impaction bone grafting in Gaucher's disease

Total hip arthroplasty in Gaucher's disease has been associated with high rates of loosening after all types of arthroplasty. We present a patient with type 1 Gaucher's disease who underwent revision cemented total hip arthroplasty for aseptic loosening after 12 months of enzyme replacement therapy. Major osteolysis was managed by impaction morcellized bone grafting. An excellent clinical and radiographic result was obtained at 5-year follow-up. Enzyme replacement therapy combined with modern revision techniques may offer improved outcomes for patients with Gaucher's disease.     

后路微创髋关节置换与后侧髋关节置换术后临床效果比较

目的比较经皮穿刺辅助保留关节囊全髋(SuperPATH)入路与后外路髋关节置换的术后临床疗效。 方法收集来自南方医科大学第五附属医院,广州市正骨医院以及广州市陆军总医院3个单位关节外科共102例接受单侧髋关节置换患者,纳入标准包括：初次人工全髋关节置换;股骨头缺血坏死3、4期;患者年龄大于50岁,小于80岁;股骨颈骨折Garden Ⅲ,Ⅳ型。排除标准为：随访资料不完整;髋臼发育不良Crowe 3型和4型;髋关节强直。使用随机数字表随机分为2组,实验组56例接受Surperpath入路微创人工全髋关节置换;对照组56例接受常规后外侧入路人工全髋关节置换,通过SPSS 13.0两组样本t检验比较实验组与对照组手术切口长度,术中出血量,手术时间以及术后功能评分。 结果SuperPATH微创髋关节置换组较后侧入路髋关节置换组手术切口长度较短(t＝25.960, P<0.01),术中出血量较少(t＝12.600,P<0.01),术后功能评分较高(术后1月t＝3.340,术后6月t＝0.410,P<0.01),手术时间较对照组长(t＝10.550,P<0.01)。 结论Super PATH微创髋关节置换术创伤较小,术中出血量较少,术后功能恢复良好,切口较少,对于熟练掌握该手术的医生针对适应症明确的患者可选该手术方式。     

带翼加强杯Ⅰ期治疗髋臼合并同侧股骨颈骨折

目的探讨带翼加强杯在Ⅰ期全髋关节置换治疗髋臼骨折合并同侧股骨颈骨折中的应用。方法对12例合并同侧股骨颈骨折的髋臼骨折行Ⅰ期全髋关节置换术(total hip arthroplasty,THA)。伤后5~18 d接受THA,12例均采用带翼加强杯合并自体植骨行髋臼侧固定,股骨侧均采用生物型固定。根据Harris评分和X线片对其临床效果进行评估。结果 12例患者均得到随访,平均随访时间3年9个月(2年1个月~5年7个月)。2例出现异位骨化,无脱位,未见假体移位及透亮带,无再翻修病例。术后Harris评分平均90分,较术前平均改善51分。所有随访患者髋关节功能均有明显改善,随访期内未发现假体松动。结论应用带翼加强杯行Ⅰ期全髋关节置换术是治疗髋臼骨折合并同侧股骨颈骨折的有效方法,这种方法强调髋臼重建结构的稳定性,避免了切开复位内固定引起的股骨头坏死等严重髋关节并发症,能显著改善关节功能,避免多次手术,减少患者的精神和经济负担。     

人工全髋关节置换联合自体股骨头结构性植骨及转子下截骨治疗Crowe Ⅳ型髋关节发育不良的短期随访

目的：探讨联合自体股骨头结构性植骨及股骨转子下截骨的人工全髋关节置换术治疗CroweⅣ型髋关节发育不良（developmental dysplasia of the hip, DDH）的短期临床效果。方法回顾性分析2010年1月至2013年12月于我院手术治疗CroweⅣ型DDH的48例（48髋）病人的临床资料,手术均使用非骨水泥组配式S?ROM假体行全髋关节置换术,髋臼均行自体股骨头结构性植骨,并用2~3枚空心拉力螺钉固定,股骨均行小转子下截骨。记录术中截骨长度,术中出血量及输血例数,术中股骨远端骨折例数,术后股神经损伤及静脉血栓发生例数,术后假体松动、假体周围骨折及感染例数。比较病人术前术后的疼痛视觉模拟量表（visual analogue scale, VAS）评分、Harris评分及双下肢长度差异。结果2例术中出现股骨远端骨折,予以钢丝捆扎术后3个月复查提示骨折端骨性愈合。3例术后出现股神经损伤症状,术后1个月复查时症状均消失。术前患肢较健肢平均短缩（6.3±0.9）cm,患髋的Harris评分为（38.6±5.3）分;术后随访2年时的患肢较健肢平均短缩（1.9±0.7）cm,Harris评分为（89.2±1.4）分;手术前后各指标差异均有统计学意义（均P＜0.05）。随访期间无假体松动、感染,无假体周围骨折。结论联合自体股骨头结构性植骨及股骨转子下截骨的人工全髋关节置换术是治疗CroweⅣ型DDH的一种有效的手术方式,值得进一步研究。